Joshua Brody

Joshua Brody, MD, is a prominent figure in the field of cancer immunotherapy, currently serving as the Director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute, part of the Icahn School of Medicine at Mount Sinai Hospital in New York. He has been with Mount Sinai since 2011, where he has established a robust clinical program and a translational Cancer Immunotherapy Lab focused on developing novel therapies for various cancers, particularly lymphomas, breast cancer, and head/neck cancer.12

Education and Career

Dr. Brody earned his medical degree from the State University of New York at Stony Brook and completed his fellowship training at Stanford University Medical Center. His early exposure to cancer research, influenced by his father—a pioneering cancer immunotherapy physician-scientist—shaped his career path.2 He is also an Associate Professor at the Icahn School of Medicine, where he contributes to both teaching and research.

Research Focus

Dr. Brody's research primarily investigates immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies. His work addresses challenges such as antigen escape in follicular lymphoma (FL), aiming to characterize tumor cells to enhance treatment efficacy and prevent relapse.23 He has received funding from notable organizations like the National Institutes of Health and the Cancer Research Institute, underscoring his contributions to advancing cancer treatment.1

Publications and Contributions

His findings have been published in prestigious journals such as Nature Medicine and Cancer Discovery, reflecting his significant impact on the field.1 Dr. Brody is also involved in professional organizations like the Society for the Immunotherapy of Cancer and has received multiple awards for his research contributions.

Patient Care Philosophy

Dr. Brody emphasizes a collaborative approach with patients to ensure that treatment plans align with their needs and preferences, aiming for optimal outcomes while maintaining quality of life.12

In addition to his clinical and research roles, Dr. Brody is active on social media, sharing insights related to his work and advancements in cancer immunotherapy.4